Sort
51,593 grants matching “hepatitis”
Mechanisms of repeated control of acute hepatitis C infection in humans
$794,328Andrea L Cox · Johns Hopkins University · U19 · FY2018 · AI
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy
$794,282Vincent Lo Re · University Of Pennsylvania · R01 · FY2019 · AI
Rhesus HHV-8 homologue in AIDS-related malignancies
$794,238Scott W Wong · Oregon Health & Science University · R01 · FY2017 · CA
Dynamics of antigen specific B and Tfh responses during acute and chronic HCV
$794,050Arash Grakoui · Emory University · R01 · FY2019 · AI
Structure And Assembly Of The Hepatitis B Nucleocapsid Protein
$794,028Paul T Wingfield · Arthritis, Musculoskeletal, Skin Dis · Z01 · FY2007 · AR
Control of Viral Pathogenesis by Regulation of 2-5A Levels
$793,942Susan R. Weiss · University Of Pennsylvania · R01 · FY2020 · AI
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network
$793,806Jose Szapocznik · University Of Miami School Of Medicine · UG1 · FY2015 · DA
Retroviral infection and new modulators of the MHCII pathway
$793,725Tatyana V. Golovkina · University Of Chicago · R01 · FY2025 · AI
Impact of Structural Racism and Discrimination on Liver Disease Disparities in High-Risk Asian American Populations
$793,566Grace X Ma · Temple Univ Of The Commonwealth · R01 · FY2024 · MD
ATECAR: Asian Training, Education on Cancer & Research
$793,449Grace X Ma · Temple Univ Of The Commonwealth · U01 · FY2008 · CA
Leveraging Social Networks to Increase COVID-19 Testing Uptake: A Comparison of Credible Messenger and Chain Referral Recruitment Approaches
$793,293Katherine S Elkington · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · UG1 · FY2021 · DA
Tirzepatide for treatment of familial partial lipodystrophy
$793,098Elif Arioglu Oral · University Of Michigan At Ann Arbor · R01 · FY2025 · DK
Discovering Small Molecule Biased Agonists for the Neuropeptide S Receptor
$793,020Scott P Runyon · Research Triangle Institute · R01 · FY2021 · MH
Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria
$792,986Lifang Hou · Northwestern University At Chicago · U54 · FY2020 · CA
Vascular Targeting of Nanocarriers for RNA
$792,842Vladimir R Muzykantov · University Of Pennsylvania · R01 · FY2023 · HL
Dissecting virus neutralizing determinants to guide HCV vaccine development
$792,744Mansun Law · Scripps Research Institute, The · R56 · FY2013 · AI
Pathogenesis of Hepatitis B Virus in Transgenic Mice
$792,726Francis Vincent Chisari · Scripps Research Institute, The · R01 · FY2008 · CA
NK/DC Cross-Talk and Antiviral Response
$792,714Luis J. Montaner · Wistar Institute · R01 · FY2010 · AI
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV
$792,500Suneil Krishna Koliwad · University Of California, San Francisco · R01 · FY2017 · DK
Risk Factors for AIDS among Persons Who Inject Drugs: HIV and COVID-19
$792,422Don C Des Jarlais · New York University · R01 · FY2021 · DA
HIV, HCV, Hippo, and Liver Disease Progression
$792,339Raymond T Chung · Massachusetts General Hospital · R01 · FY2018 · AI
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in Ukraine
$792,012Frederick Lewis Altice · Yale University · R01 · FY2021 · DA
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease
$791,956D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · UG3 · FY2021 · TR
A systems immunology approach for predicting poor responses to Hepatitis B vaccination
$791,641Ramin Herati · New York University School Of Medicine · R01 · FY2022 · AI
Atlanta Center for the Childhood Liver Disease Research Network (ChiLDReN)
$791,531Saul Joseph Karpen · Emory University · U01 · FY2019 · DK